Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status.

BACKGROUND Glioblastomas with a specific mutation in the isocitrate dehydrogenase 1 (IDH1) gene have a better prognosis than gliomas with wild-type IDH1. METHODS Here we compare the IDH1 mutational status in 172 contrast-enhancing glioma patients with the invasion profile generated by a patient-specific mathematical model we developed based on MR imaging. RESULTS We show that IDH1-mutated contrast-enhancing gliomas were relatively more invasive than wild-type IDH1 for all 172 contrast-enhancing gliomas as well as the subset of 158 histologically confirmed glioblastomas. The appearance of this relatively increased, model-predicted invasive profile appears to be determined more by a lower model-predicted net proliferation rate rather than an increased model-predicted dispersal rate of the glioma cells. Receiver operator curve analysis of the model-predicted MRI-based invasion profile revealed an area under the curve of 0.91, indicative of a predictive relationship. The robustness of this relationship was tested by cross-validation analysis of the invasion profile as a predictive metric for IDH1 status. CONCLUSIONS The strong correlation between IDH1 mutation status and the MRI-based invasion profile suggests that use of our tumor growth model may lead to noninvasive clinical detection of IDH1 mutation status and thus lead to better treatment planning, particularly prior to surgical resection, for contrast-enhancing gliomas.

[1]  C. Hoogenraad,et al.  IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo , 2011, Annals of neurology.

[2]  Kristin R. Swanson,et al.  The Evolution of Mathematical Modeling of Glioma Proliferation and Invasion , 2007, Journal of neuropathology and experimental neurology.

[3]  Jacob G. Scott,et al.  Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift? , 2011, Neuro-oncology.

[4]  David Basanta,et al.  The role of IDH1 mutated tumour cells in secondary glioblastomas: an evolutionary game theoretical view , 2011, Physical biology.

[5]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[6]  J. Uhm.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .

[7]  K. Swanson,et al.  A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle , 2007, British Journal of Cancer.

[8]  K. Aldape,et al.  IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. , 2014, Neuro-oncology.

[9]  Gargi Chakraborty,et al.  Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. , 2009, Cancer research.

[10]  Robert J Gillies,et al.  The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. , 2009, Cancer research.

[11]  Albert Lai,et al.  Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. , 2009, Cancer research.

[12]  J. Mackey,et al.  Metabolic Modulation of Glioblastoma with Dichloroacetate , 2010, Science Translational Medicine.

[13]  Alexander R A Anderson,et al.  Quantifying the Role of Angiogenesis in Malignant Progression of Gliomas: in Silico Modeling Integrates Imaging and Histology Nih Public Access Author Manuscript Introduction , 2011 .

[14]  David T. W. Jones,et al.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. , 2009, Neuro-oncology.

[15]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[16]  J. Murray,et al.  Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion , 2003, Journal of the Neurological Sciences.

[17]  Kristin R. Swanson,et al.  Quantifying glioma cell growth and invasion in vitro , 2008, Math. Comput. Model..

[18]  T. Cloughesy,et al.  Relationship between Tumor Enhancement, Edema, IDH1 Mutational Status, MGMT Promoter Methylation, and Survival in Glioblastoma , 2012, American Journal of Neuroradiology.

[19]  P. Kleihues,et al.  IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.

[20]  H. Duffau,et al.  1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth , 2012, Journal of Neuro-Oncology.

[21]  K Hendrickson,et al.  Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach , 2010, Physics in medicine and biology.

[22]  E. T. Gawlinski,et al.  Acid-mediated tumor invasion: a multidisciplinary study. , 2006, Cancer research.

[23]  Kristin R. Swanson,et al.  Discriminating Survival Outcomes in Patients with Glioblastoma Using a Simulation-Based, Patient-Specific Response Metric , 2013, PloS one.

[24]  Philip K Maini,et al.  Tumour-stromal interactions in acid-mediated invasion: a mathematical model. , 2010, Journal of theoretical biology.

[25]  Andrey Korshunov,et al.  Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.

[26]  S. Lewandowsky.  PLOS ONE 2013 , 2015 .

[27]  M. J. van den Bent,et al.  Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? , 2011, The Lancet. Oncology.

[28]  Kieran Smallbone,et al.  Mathematical modelling of tumour acidity. , 2008, Journal of theoretical biology.

[29]  D. Cahill,et al.  From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. , 2013, Neurosurgical focus.